Skip To Main Content
Barry A. Borlaug on Muck Rack

Barry A. Borlaug

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, heart, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, JAMA Cardiology, Medscape, The New England Journal of Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry A.

Contact Barry A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions

|
By Muhammad Khan, Barry A. Borlaug, Javed Butler
| JACC (Journal of the American College of Cardiology)
JACC Journals › JACC › Archives › Vol. 88 No. 4 JACC State-of-the-Art Review : JACC Volume 88, Number 4 Get full access to this article View all available purchase options and get full access to this article. References 1. Funk-Hilsdorf T.C., Behrens F., Grune J., Simmons S. Dysregulated immunity in pulmonary hypertension: from companion to composer. Front Physiol. 2022;13:819145 https://doi.org/10.3389/fphys.2022.819145. 2. Hoeper M.M., Humbert M., Souza R., et al.
Open in Who Shared Issue with article?

Right Ventricular Metrics as End Points in Clinical Trials : A Review

|
By Elena Surkova, Bálint K. Lakatos, Hannah R. Kempton, Alex Lee Verified, JoAnn Lindenfeld, Joao Lima, Stephan Rosenkranz, Barry A. Borlaug, Jörg Hausleiter, Daniel Burkhoff, Denisa Muraru, Martin Leon, Béla Merkely, Rebecca T. Hahn, Attila Kovacs
| JAMA Cardiology
Right Ventricular Metrics as End Points in Clinical Trials: A Review Abstract Importance Clinical trials in cardiovascular medicine aim to deliver high-quality evidence with greater efficiency, including smaller sample sizes and shorter timelines. The selection of sensitive and reliable end points is central to this goal.
Open in Who Shared Issue with article?

Updated HFmrEF Guidelines From HFSA Support Standard HFrEF Treatment

|
By Barry A. Borlaug
| consultantlive.com
The Heart Failure Society of America (HFSA) has released a new scientific statement encouraging the acceptance of heart failure with mildly reduced ejection fraction (HFmrEF) as its own distinct condition.1 Prior to the statement’s release, HFmrEF has largely been considered a gray zone in between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), and as a result has been understudied.
Open in Who Shared View Duplicates (2) Issue with article?
See all 109 licensed articles (118 Total)